Document:

wndm_ex103.htm

Exhibit 10.3

 

THIS SENIOR SECURED CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF ARE OFFERED AND SOLD WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

 

WOUND MANAGEMENT TECHNOLOGIES, INC. AND SUBSIDIARIES

SENIOR SECURED CONVERTIBLE PROMISSORY NOTE

 

	
$600,000.00 

	
June 15, 2015

 

 Addison, Texas

 

FOR VALUE RECEIVED, Wound Management Technologies, Inc., a Texas corporation (“WTI”), Wound Care Innovations, LLC, a Nevada limited liability company (“WCI”), Resorbable Orthopedic Products, LLC, a Texas limited liability company (“ROP”), and BioPharma Management Technologies, Inc., a Texas corporation (“BMT”), hereby jointly and severally promise to pay to The S. Oden Howell Revocable Trust (“Lender”), the principal sum of Six Hundred Thousand Dollars ($600,000.00), or such lesser amount as shall equal the outstanding principal amount hereof, together with interest from the date of this Note on the unpaid principal balance at a rate equal to ten percent (10%) per annum, compounding annually, computed on the basis of the actual number of days elapsed and a year of 365 days. WTI, WCI, ROP and BMT are sometimes each referred to herein as a “Borrower”, and collectively, as the “Borrowers”. Payment of principal and interest on this Note shall be made in lawful money of the United States of America unless this Note is converted as described herein. All unpaid principal, together with any then unpaid and accrued interest, shall be due and payable on the later of: (i) the third (3rd) anniversary date of this Note; or (ii) when, upon or after the occurrence of an Event of Default, such amounts are declared due and payable by Lender or made automatically due and payable in accordance with the terms hereof (the “Maturity Date”).

 

Prior to the Maturity Date, this Note may be prepaid in whole or in part, provided that Borrowers provide ten (10) days written notice of their intent to prepay the Note to Lender. Lender shall have the option to convert any amounts to be prepaid as provided in Section 5 below.

 

The following is a statement of the rights of Lender and the conditions to which this Note is subject, and to which Lender, by the acceptance of this Note, agrees:

 

	
1.  

	
Definitions.  As used in this Note, the defined terms as set forth in the Term Loan Agreement between the Lender and Borrowers of even date herewith (the “Loan Agreement”) shall have the same meanings as attributed thereto.

 

	
2.  

	
Interest.  Accrued interest on this Note shall be payable on the Maturity Date.

 

	
3.  

	
Events of Default.  The occurrence of an event constituting an Event of Default as set forth in the Loan Agreement shall constitute an Event of Default under this Note.

 

	
4.  

	
Rights of Lender upon Default.  Upon the occurrence or existence of any Event of Default and at any time thereafter during the continuance of such Event of Default, the Lender, by written notice to Borrowers, may declare all outstanding accrued interest and principal payable by Borrowers under this Note to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived. Upon the occurrence, and during the existence, of any Event of Default, immediately and without notice, all outstanding principal and accrued interest payable by Borrowers hereunder shall automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived. In addition to the foregoing remedies, upon the occurrence, and during the existence, of any Event of Default (but only if the default is not cured within ten (10) business days after written notice of default has been delivered by Lender to Borrowers) Lender may exercise its rights under the Security Agreement and any other right power or remedy otherwise permitted by law, either by suit in equity or by action at law.

 

  

1

  

 

	
5.  

	
Conversion.

 

	
(a)  

	
Preferred Stock.  Subject to compliance with applicable securities laws and at the option of Lender, at any time prior to the Maturity Date with written notice to Borrowers, all of the unpaid principal and accrued interest under this Note shall be converted automatically into fully paid and nonassessable shares of WTI’s Series C Convertible Preferred Stock at a conversion price of $70 per share (the “Conversion Price”).

 

	
(b)  

	
Fractional Shares; Interest; Effect of Conversion.  No fractional shares shall be issued upon conversion of this Note. In lieu of WTI issuing any fractional shares to Lender upon the conversion of this Note, WTI shall pay to Lender an amount equal to the product obtained by multiplying the Conversion Price by the fraction of a share not issued pursuant to the previous sentence. Upon conversion of this Note in full and the payment in full of all amounts specified in this Section 5(b), Borrowers shall be deemed to be forever released from all their obligations and liabilities under this Note.

 

	
(c)  

	
No Registration.  By accepting this Note, Lender acknowledges that (a) this Note and the shares of the Series C Convertible Preferred Stock issuable on conversion hereof will not be registered under the Securities Act of 1933, as amended, or the securities laws of any state, and may not be sold or transferred without such registration or an exemption therefrom, and will bear a legend adverting to those restrictions.

 

	
6.  

	
Successors and Assigns.  Subject to the restrictions on transfer described herein, the rights and obligations of Borrowers and Lender shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of Borrowers and Lender.

 

	
7.  

	
Waiver and Amendment.  Any provision of this Note may be amended, waived or modified upon the written consent of Borrowers and the Lender.

 

	
8.  

	
Assignment by Borrowers.  Neither this Note nor any of the rights, interests or obligations hereunder may be assigned, by operation of law or otherwise, in whole or in part, by Borrowers without the prior written consent of Lender.

 

	
9.  

	
Attorneys’ Fees.  Time is of the essence of this Note. If an Event of Default occurs and is continuing, Borrowers shall further pay to Lender the amounts provided for in Section 9.3(a) of the Loan Agreement.

 

  

2

  

 

	
10.  

	
Notices.  All notices, requests, demands, consents, instructions or other communications required or permitted hereunder shall in writing and faxed, mailed or delivered to each party at the respective addresses of the parties as set forth in the Note, or at such other address or facsimile number as Borrowers shall have furnished to Lender in writing. All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one business day after being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service of recognized standing or (v) four days after being deposited in the U.S. mail, first class with postage prepaid.

 

	
11.  

	
Waivers.  Borrowers hereby waive notice of default, presentment or demand for payment, protest or notice of nonpayment or dishonor and all other notices or demands relative to this instrument.

 

	
12.  

	
Governing Law.  This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the Commonwealth of Kentucky, without regard to the conflicts of law provisions of the Commonwealth of Kentucky, or of any other state.

 

[Signature Page Follows]

 

  

3

  

 

IN WITNESS WHEREOF, each of the undersigned, by its duly authorized officer, has executed this Note as of the day and year first above written.

 

WOUND MANAGEMENT TECHNOLOGIES, INC.

 

By: /s/ Robert H. Lutz, Jr.                                                                

 

      Robert H. Lutz, Jr.

      Chief Executive Officer and President

 

WOUND CARE INNOVATIONS, LLC

 

By: /s/ Robert H. Lutz, Jr.                                                                

 

      Robert H. Lutz, Jr.,

      Chief Executive Officer

 

RESORBABLE ORTHOPEDIC PRODUCTS, LLC

 

By: /s/ Robert H. Lutz, Jr.                                                                

 

      Robert H. Lutz, Jr.

      President

 

BIOPHARMA MANAGEMENT TECHNOLOGIES, INC.

 

By: /s/ Robert H. Lutz, Jr.                                                                

 

      Robert H. Lutz, Jr.

      President

 

4EX-10.1

 Exhibit 10.1 
  

					
	 

				

 Minerva Neurosciences, Inc. 

Non-Employee Director Compensation Plan 

Approved: June 17, 2015 

Effective: July 1, 2015 

Effective as of July 1, 2015, each non-employee member of the board of directors (the “Board”) of Minerva Neurosciences, Inc.
(the “Company”) will receive an annual cash retainer of $30,000 and the Chairman of the Board will receive an additional annual cash retainer of $50,000. The chairpersons of the Audit Committee, Compensation Committee and Nominating and
Corporate Governance Committee will receive additional annual cash retainers of $15,000, $10,000 and $7,000, respectively. Other members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee will receive
additional annual cash retainers of $7,500, $5,000 and $3,500, respectively. Each newly elected non-employee director will also receive a one-time grant of an option to purchase 25,000 shares of the Company’s common stock promptly following
election or appointment to the Board (the “Director Welcome Options”). The Director Welcome Options will vest quarterly over three years, provided that the applicable non-employee director is, as of such vesting date, then a director of
the Company. In addition, each non-employee director will be granted options to purchase 12,500 shares of the Company’s common stock per year (the “Annual Grants”). The Annual Grants will vest in equal quarterly installments over one
year, provided that the applicable non-employee director is, as of such vesting date, then a director of the Company. Non-employee directors are also reimbursed for their reasonable out-of-pocket expenses incurred in attending meetings of the Board
or of any committee thereof. 
 The following is a summary of the terms of this Non-Employee Director Compensation Plan: 

Cash 

	 	•	 	Annual retainer for Chairman of the Board – $80,000 

  

	 	•	 	Annual retainer per Board member (other than Chairman) – $30,000 

  

	 	•	 	Committee chair annual retainers: 

	 	¡ 	 	$15,000 Audit 

	 	¡ 	 	$10,000 Compensation 

	 	¡ 	 	$ 7,000 Nominating and Governance 

  

	 	•	 	Committee member annual retainers: 

	 	¡ 	 	$7,500 Audit 

	 	¡ 	 	$5,000 Compensation 

	 	¡ 	 	$3,500 Nominating and Governance 

  

	 	•	 	Retainers are paid on a quarterly basis. 

 Stock Options 

 

	 	•	 	Initial grant per Board member – 25,000 options vesting quarterly over 3 years, provided that the applicable non-employee director is, as of such vesting date, then a director of the Company 

 

	 	•	 	Annual grant per Board member – 12,500 options vesting quarterly over 1 year, provided that the applicable non-employee director is, as of such vesting date, then a director of the Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]